Dentsply Sirona: 3 Key Takeaways for Long-Term Investors

Source Motley_fool

Key Points

  • Management reduced full-year 2026 sales guidance to approximately $3.5 billion.

  • Wellspect Healthcare revenue grew 10% year over year to $92 million.

  • Clinical education investments in North America increased sixfold year over year.

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

On its third-quarter 2026 earnings call, held on Nov. 5, 2026, Dentsply Sirona (NASDAQ:XRAY) announced lower full-year net sales and earnings guidance. Revenue fell 7.6% as reported, driven by weakness across dental equipment lines. Long-term investors must weigh these operational headwinds against ongoing investments in commercial sales teams and product innovation.

Three things management said stand out.

1. Full-Year Revenue and Earnings Guidance Crept Lower

Management lowered its net sales expectations to approximately $3.5 billion and reduced adjusted earnings per share, a key profitability metric, to between $1.20 to $1.30. Higher distribution costs and weaker equipment demand created headwind pressures that extra cost cuts didn't fully offset.

We now expect full-year net sales of approximately $3.5 billion versus the range of $3.5 billion-$3.6 billion previously, and adjusted EPS of $1.20-$1.30 from $1.40-$1.50, excluding the $0.17 one-time gain from tariff refunds.
-- Dan Scavilla, President and Chief Executive Officer

2. Heavy Clinical Education Spending Aims to Fuel Long-Term Adoption

Management multiplied its spending on clinical training programs in North America to build practitioner loyalty and drive usage across its endodontic, or root canal treatment, product line. This commercial strategy prioritizes product adoption over short-term operating margin expansion.

Our second half 2026 clinical education investment in North America is six times greater than last year's level, including more than 160 endo courses and expanded hands-on programs.
-- Dan Scavilla, President and Chief Executive Officer

3. Commercial Execution Drives Growth in Wellspect Healthcare

The Wellspect Healthcare business, which produces continent urinary catheter products, delivered 10% revenue growth during the quarter to reach $92 million. Focused commercial spending expanded the division's reach in the $7 billion market.

Investments in new products and U.S. commercial capabilities are supporting broader market reach and continued growth.
-- Dan Scavilla, President and Chief Executive Officer

Looking Ahead

Green shoots in U.S. dental implants and restorative lines signal initial operational progress, and leadership is pushing to convert these early gains into sustainable organic momentum. The business continues building out dedicated teams for dental support organizations, which are corporate dental practice chains, while sharpening research and development discipline. Management is tracking distributor inventory levels, sales force vacancy rates, and pricing discipline to evaluate progress.

The task is now to extend that progress across the portfolio and deliver more consistent results.
-- Dan Scavilla, President and Chief Executive Officer

Stabilizing core equipment sales while maintaining cost control remains central to deleveraging, which means paying down debt to improve financial flexibility. Capital allocation priorities lean heavily toward debt reduction alongside disciplined reinvestment in commercial execution.

My priorities are to translate these capabilities into more consistent execution, disciplined investment, and stronger cash generation.
-- John Fortson, Executive Vice President and Chief Financial Officer

Should you buy stock in Dentsply Sirona right now?

Before you buy stock in Dentsply Sirona, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Dentsply Sirona wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*

Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 16, 2026.

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
AMD Just Had Its Biggest Run Against Nvidia Since 1999. Can It Survive Earnings?AMD outperformed Nvidia by 53.2 percentage points over five trading days, according to The Kobeissi Letter. That is the widest gap between the two chipmakers since Nvidia went public in January 1999.T
Author  Beincrypto
21 hours ago
AMD outperformed Nvidia by 53.2 percentage points over five trading days, according to The Kobeissi Letter. That is the widest gap between the two chipmakers since Nvidia went public in January 1999.T
placeholder
3 Key Events in the Coming Week That Could Move AI Stocks and CryptoNvidia earnings, Fed minutes, and Anthropic’s IPO all land between Tuesday and Thursday in the coming week. Each will test an AI selloff that has also spilled into crypto.Rates add a second layer of r
Author  Beincrypto
21 hours ago
Nvidia earnings, Fed minutes, and Anthropic’s IPO all land between Tuesday and Thursday in the coming week. Each will test an AI selloff that has also spilled into crypto.Rates add a second layer of r
placeholder
Weekly Market Wrap: Nvidia Lost Its CEO, but AI Stocks Found New LeadersNvidia’s leadership shock has put the AI trade in focus, but other technology stocks are emerging as new market leaders. Explore this week’s key market moves, shifting investor sentiment and what Australian traders should watch next.
Author  Mark Garro
21 hours ago
Nvidia’s leadership shock has put the AI trade in focus, but other technology stocks are emerging as new market leaders. Explore this week’s key market moves, shifting investor sentiment and what Australian traders should watch next.
placeholder
Bitcoin’s Fall to $62,000 Sparks Market Manipulation ClaimsBitcoin plunged to nearly $62,000 on November 15, its lowest level since July. The drop wiped out months of gains and triggered more than $2 billion in liquidations.Now, several analysts claim that la
Author  Beincrypto
21 hours ago
Bitcoin plunged to nearly $62,000 on November 15, its lowest level since July. The drop wiped out months of gains and triggered more than $2 billion in liquidations.Now, several analysts claim that la
placeholder
Bitcoin Loses Key 200-Day Average: Is $67,000 Next?Bitcoin price fell below its 200-day moving average of $73,137 on Thursday. It’s one of the most closely watched indicators in crypto because it helps investors understand whether Bitcoin’s long-term
Author  Beincrypto
Nov 13, Fri
Bitcoin price fell below its 200-day moving average of $73,137 on Thursday. It’s one of the most closely watched indicators in crypto because it helps investors understand whether Bitcoin’s long-term
goTop
quote